Exor N.V. (EXO.AS)
| Previous Close | 102.10 |
| Open | 102.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 101.10 - 102.70 |
| 52 Week Range | 72.44 - 105.15 |
| Volume | |
| Avg. Volume | 137,396 |
| Market Cap | 34.773B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 5.50 |
| EPS (TTM) | 18.39 |
| Earnings Date | Apr 11, 2024 |
| Forward Dividend & Yield | 0.46 (0.45%) |
| Ex-Dividend Date | May 30, 2024 |
| 1y Target Est | 117.60 |
- GlobeNewswire
Exor Press Release - Periodic Report on the Buyback Program
Amsterdam, 22 April 2024 EXOR N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM Exor N.V. (AMS: EXO) (“Exor” or the “Company”) announces that, under the first tranche of the share buyback program of up to €125 million announced on 15 April 2024 (the “first tranche”), the Company has completed the following transactions on Euronext Amsterdam and CBOE DXE: EURONEXT AMSTERDAM Trading DateNumber of ordinary shares purchasedAverage price per share excluding fees (€)Total consideration excluding fees (€)15
- GlobeNewswire
Exor Press Release - Restart of Announced Share Buyback Program
Amsterdam, 15 April 2024 EXOR N.V. ANNOUNCES THE RESTART OF THE ANNOUNCED SHARE BUYBACK PROGRAM Exor N.V. (the “Company”) announces today that it will restart the share buyback program announced on 13 September 2023 (the “Program”) for the remaining amount of up to € 250 million of ordinary shares to reduce Exor’s share capital in line with the announcement made on 13 September 2023. The Company will start on 15 April 2024 with a first tranche of purchases up to €125 million, which is expected t
ReutersAgnellis' Exor targets growth in healthcare sector
Exor, the investment arm of the Agnelli family, has a growing interest in the healthcare industry, where it has already invested almost 4 billion euros ($4.3 billion), CEO John Elkann said on Thursday. "The increased cost of healthcare services combined with a shortage of medical staff is driving demand for innovative new approaches to tackle global health problems," he said in his annual letter to Exor shareholders. Exor views healthcare as a "long-term, structural growth sector," added Elkann, the scion of the Agnelli family and chair of automakers Stellantis and Ferrari.
